<SEC-DOCUMENT>0001140361-21-029039.txt : 20210820
<SEC-HEADER>0001140361-21-029039.hdr.sgml : 20210820
<ACCEPTANCE-DATETIME>20210820164535
ACCESSION NUMBER:		0001140361-21-029039
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210820
DATE AS OF CHANGE:		20210820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		211194368

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>brhc10028241_defa-14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES <font style="color: rgb(0, 0, 0);">SECURITIES AND EXCHANGE COMMISSION</font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 8-K</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CURRENT REPORT</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0);">Date of Report (Date of earliest event reported): <font style="font-weight: bold;">August 20, 2021</font></div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">Brooklyn ImmunoTherapeutics, Inc.<br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 32.62%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware<br>
              </div>
            </td>
            <td style="width: 33.62%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">001-11460<br>
              </div>
            </td>
            <td style="width: 33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">31-1103425<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 32.62%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>
            <td style="width: 33.62%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Commission File Number)</div>
            </td>
            <td style="width: 33%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(IRS Employer Identification No.)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">140 58th Street, Building A, Suite 2100</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center;">&#160;</div>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn, New York</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center;">&#160;</div>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">11220<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center;">&#160;</div>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;"><font style="color: rgb(0, 0, 0);">Registrant&#8217;s telephone number, including area code:</font>&#160;<font style="font-weight: bold; color: rgb(0, 0, 0);">(212) 582-1199</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>
      <div>&#160;
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;</td>
              <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
      </div>
      <div>Securities registered pursuant to Section 12(b) of the Act:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of each class</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">
              <div>&#160;</div>
            </td>
            <td style="width: 18%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading symbol</div>
            </td>
            <td style="width: 1%; vertical-align: middle;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of each exchange on which registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">Common Stock, par value $0.005 per share<br>
                </div>
              </div>
            </td>
            <td style="width: 1%; vertical-align: middle;">
              <div>&#160;</div>
            </td>
            <td style="width: 18%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);">BTX<br>
              </div>
            </td>
            <td style="width: 1%; vertical-align: middle;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%; vertical-align: top; text-align: center;">NYSE American<br>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div><font style="color: rgb(0, 0, 0);">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:</font><font style="color: rgb(0, 0, 0);">Emerging growth company&#160; </font>&#9744;</div>
      <div>&#160;</div>
      <div style="color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section&#160;13(a) of the Exchange Act. &#9744;</div>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="color: rgb(0, 0, 0);">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter">
          <div style="text-align: center;"></div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><font style="font-weight: bold;">Item 8.01</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="font-weight: bold;">Other Events.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">On August 20, 2021, we called to order our 2021 Annual Meeting of Stockholders, or the Annual Meeting. At that time, there were not present or represented by proxy a sufficient number of shares
        of common stock to constitute a quorum. As previously disclosed in our proxy materials for the Annual Meeting, in order for a quorum to be present at the Annual Meeting, at least 36,679,575 shares of common stock, or approximately 83% of the total
        outstanding shares as of the record date of 5 p.m., Eastern time, on June 21, 2021, must be present virtually or represented by proxy at the meeting.</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">At the Annual Meeting on August 20, 2021, we adjourned the Annual Meeting until September 3, 2021 at 9 a.m., Eastern time, in order to provide an opportunity to solicit additional
          proxies that will constitute a quorum and will enable us to proceed with consideration of the proposals to be voted on by stockholders at the Annual Meeting. At that time, the Annual Meeting will be reconvened virtually at </font><font style="font-style: italic;">www.virtualshareholdermeeting.com/BTX2021</font><font style="color: rgb(0, 0, 0);">. The record date for the Annual Meeting remains 5 p.m., Eastern time, on June 21, 2021. Stockholders who have previously submitted
          their proxies or otherwise voted and who do not want to change their vote do not need to take any further actions.</font></div>
      <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
        </font></div>
      <div style="text-align: justify;">
        <div style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
          <div>We have engaged a proxy solicitor, Alliance Advisors, LLC, to assist the board of directors and management in obtaining adequate votes to achieve the
            required quorum for the Annual Meeting. We estimate that our proxy solicitation fees payable to Alliance Advisors, LLC will total approximately $7,500.</div>
        </div>
        <font style="color: rgb(0, 0, 0);"> </font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. We strongly encourage all of our stockholders to read the definitive proxy statement we filed with
        the Securities and Exchange Commission on July 1, 2021, the supplement to the definitive proxy statement we filed with the Securities and Exchange Commission on July 26, 2021, and other proxy materials relating to the Annual Meeting, which are
        available free of charge on the Securities Exchange Commission&#8217;s website at <font style="font-style: italic;">www.sec.gov</font>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">On August 20, 2021, we issued a press release entitled &#8220;Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum.&#8221; A copy of the press release is
        furnished as Exhibit 99.1 to this report and is incorporated herein by reference.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">The information contained in this Item 8.01 and in the press release furnished as Exhibit 99.1 to this report shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act
        of 1934 or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933. The information contained in this Item 8.01 and in the press release furnished as Exhibit 99.1 to this report shall not be
        incorporated by reference into any filing with the Securities and Exchange Commission made by us whether made before or after the date hereof, regardless of any general incorporation language in such filing.</div>
      <div>&#160;</div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">

              <tr style="vertical-align: top;">
                <td style="vertical-align: top; width: 45pt;">
                  <div style="text-align: justify;"><font style="font-weight: bold;">Item 9.01</font></div>
                </td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;"><font style="font-weight: bold;">Financial Statements and Exhibits.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>&#160;</div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 27pt;">
                <div style="text-align: justify;"><font style="font-weight: bold;">(d)</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify;"><font style="font-weight: bold;">Exhibits.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 7.69%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">
              <div style="text-align: center; font-weight: bold;">&#160;</div>
            </td>
            <td style="width: 91%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.69%; vertical-align: top;">
              <div><a href="brhc10028241_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Press Release of Brooklyn ImmunoTherapeutics, Inc. dated August 20, 2021</div>
            </td>
          </tr>
          <tr>
            <td style="width: 7.69%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 91%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 7.69%; vertical-align: top;">
              <div>104</div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 91%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Cover Page Interactive Data File (embedded within the XBRL document)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter">
          <div style="text-align: center;"></div>
        </div>
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div>BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ <font style="font-variant: small-caps;">Howard J. Federoff</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div>Howard J. Federoff</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">
              <div><br>
              </div>
            </td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer and President</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">
              <div>Dated: August 20, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10028241_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: center;">
        <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font></div>
        <div><br>
        </div>
        <img src="image00001.jpg"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M3"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Brooklyn, NY</font> &#8211; August 20, 2021 &#8211; Brooklyn
        ImmunoTherapeutics, Inc. (NYSE American: BTX) (&#8220;Brooklyn&#8221;), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases,
        today announced<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</font>that its 2021 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;), scheduled to be held at 9 a.m., Eastern time, on August 20, 2021, was convened and adjourned,
        without any business being conducted, due to lack of the required quorum.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In order to have a quorum that enables Brooklyn to proceed with its Annual Meeting, at least 83% of the shares of common stock outstanding as of 5 p.m., Eastern time,
        on June 21, 2021 (the record date for the Annual Meeting) must be present virtually or represented by proxy at the Annual Meeting. There were fewer than 83% of the shares entitled to vote present, either virtually or by proxy at the meeting on
        August 20, 2021. In the absence of a quorum as of August 20, 2021, the Annual Meeting of Stockholders was adjourned to 9 a.m., Eastern time, on Friday, September 3, 2021, to allow additional time for Brooklyn&#8217;s stockholders to vote on the proposals
        set forth in Brooklyn&#8217;s definitive proxy statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 1, 2021, as amended by a supplement filed with the SEC on July 26, 2021.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">During the current adjournment, Brooklyn continues to solicit votes from its stockholders with respect to the proposals set forth in Brooklyn&#8217;s proxy statement, as
        supplemented. Brooklyn has engaged a proxy solicitor, Alliance Advisors, LLC, to assist the board of directors and management in obtaining adequate votes to achieve the required quorum for the Annual Meeting.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Only stockholders of record, as of the record date, June 21, 2021, are entitled to and are being requested to vote. Proxies previously submitted in respect of the
        Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.</div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn encourages all stockholders of record as of 5 p.m., Eastern time, on June&#160;21, 2021 whom have not yet voted to do so by
          September 2, 2021 at 11:59 p.m., Eastern time. Stockholders who have any questions or require any assistance with completing a proxy or voting instruction form or who do not have the required materials, may contact our Proxy Solicitation agent,
          Alliance Advisors at (855) 835-8314.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If the number of additional shares of common stock voted at the adjourned Annual Meeting is not sufficient to reach a quorum, Brooklyn may determine to adjourn the
        Annual Meeting again, which would require Brooklyn to incur additional costs.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Important Information</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This material may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on September 3, 2021. In connection with the Annual
        Meeting, Brooklyn filed with the SEC a definitive proxy statement on July&#160;1, 2021 and a supplement thereto on July&#160;26, 2021. BEFORE MAKING ANY VOTING DECISIONS, STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, THE SUPPLEMENT AND ANY
        OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. A notice of internet availability of proxy materials containing instructions on how to access the definitive proxy statement and a
        copy of the proxy supplement were mailed to stockholders who are entitled to vote at the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. Brooklyn&#8217;s proxy statement and any other
        materials filed by Brooklyn with the SEC can be obtained free of charge at Brooklyn&#8217;s website investor.brooklynitx.com/financials/sec-filings/default.aspx or the SEC's website at www.sec.gov.</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Brooklyn ImmunoTherapeutics</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M25"></a>Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood
        disorders, and monogenic diseases.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn&#8217;s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in
        Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome,
        solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M34"></a>###</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M36"></a><a name="z_DV_M37"></a><a name="z_DV_M38"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Investor Relations
          Contact:</font><font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
        </font>CORE IR</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">516-222-2560</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">investors@brooklynitx.com</div>
      <div>&#160;</div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Media Contact:</font><font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>Jules Abraham<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>CORE IR<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>917-885-7378<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>julesa@coreir.com<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font><a name="z_DV_X0"></a></font><br>
      </div>
      <div>&#160;
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !  /X# 2(  A$! Q$!_\0
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MN)-O5@F#M'IDXYKK/VE_^1^L_P#L'I_Z&]/_ &?=-2V\96-[>R,D]U;S?8X
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M1>?%&9$F & >.0<=?YUPGQ/\9W'Q*\0:=IV@V<YMHV*6T+#]Y-(W5R!T  _
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+445RG6%%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
